MAPT and Brain atrophy: Added to these diagnostic criteria is a category of biomarkers looking at brain amyloid studied by positron emission tomography (PET) and in cerebrospinal fluid (CSF) and markers of brain atrophy by nuclear magnetic resonance, neuronal damage, by investigating levels of phosphorylated tau (P-tau) and total tau (T-tau) in CSF and fluorodeoxyglucose for the metabolic activity [9,10,11,12,13,14,15].